Cantor Fitzgerald Remains a Hold on Amag Pharmaceuticals

By Ryan Adsit

Cantor Fitzgerald analyst William Tanner reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG) yesterday and set a price target of $17. The company’s shares closed yesterday at $13.90, close to its 52-week low of $11.93.

Tanner commented:

“Makena auto-injector is approved. AMAG announced today that the Makena auto-injector was approved. Although the PK data revealed a deficiency in the C max and AMAG disclosed that the FDA commented it would likely create a review issue, we suspect most investors believed the approval would occur.”

According to, Tanner is a 4-star analyst with an average return of 11.6% and a 54.3% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Amag Pharmaceuticals is Hold and the average price target is $16, representing a 15.1% upside.

In a report issued on February 5, B.Riley FBR also assigned a Hold rating to the stock with a $16 price target.

The company has a one-year high of $25.20 and a one-year low of $11.93. Currently, Amag Pharmaceuticals has an average volume of 842.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA.